Morphine - Induced Constipation Assay
Discover how Melior’s unique phenotypic screening platforms can uncover the untapped value of your candidate therapeutic
This gastrointestinal model is a method for evaluating a test compound’s ability to alter colonic propulsive motility. More specifically, this is a model that addresses opioid-induced constipation.
This model is designed to identify pharmacological agents that can functionally antagonize or relieve the constipation produced by opioids, such as morphine, as measured by an increase in colonic propulsive activity. This model can be used to identify drugs that directly affect opioid receptors or that functionally affect morphine-induced colonic activity.
In this study, we tested the ability of Naloxone, a well-known mu-opioid receptor antagonist, on morphine-induced reductions in colonic propulsive activity (constipation).
- Like most gastrointestinal models, this model is typically performed in one day after a single administration of test article.
- It has relatively low variability and can generate statistically significant effects with group sizes of 6 to 8 animals.
- It can be used with both mice and rats.